New Entries Could Boost Generic Drug Image In Japan - JGA President
This article was originally published in PharmAsia News
Executive Summary
Japan Generics Association President Hiroyuki Sawai said the recent generics entries of Pfizer and Daiichi Sankyo could help boost the generic drug image in Japan. Sawai said the wall between innovative and generic drug makers is disappearing and the major drug makers will establish new quality and trust for the industry. Many Japanese generics manufacturers are small to mid-sized, and generic drugs are considered in Japan to be lower in quality than brand products. JGA has implemented a series of programs to emphasize the quality and safety of generic drugs. Sawai also said that compared to the EU and the U.S., Japan still lacks systemic support to stimulate generics use, and he expects the industry will grow further as the government implements promotional measures. (Click here for more - Japanese language